Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/MOIRAI)
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
A phase II non-inferiority study comparing point-of-care produced CAR T-cell to commercial CAR T-cells in patients with relapsed/refractory Non-Hodgkin Lymphoma
Sponsor Universitair Medisch Centrum Groningen
- Start (EU)
- Latest update
- Estimated end
- Not reported
Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing Nilotinib versus Imatinib with switch to Nilotinib in absence of optimal response. SUSTRENIM Study – GIMEMA CML1415
Sponsor Fondazione Gimema Franco Mandelli Onlus
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (IsKia TRIAL)
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma
Sponsor Universitair Medisch Centrum Groningen
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting?
The 2026-10-09 snapshot links Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting to 5 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Project management, Data management, among 11 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting conducted?
The linked trials record locations in 15 countries, including Netherlands, Italy, Belgium, Czechia, Germany. These are trial locations, not confirmed office locations or countries where Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting delivered services.
What can this page tell me about Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting